HORSHAM, Pa., June 13, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ:SSKN) (“STRATA”) a medical
technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products
for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will
participate in a panel discussion, titled “New Medical Dermatology Treatments Which Target Established Large Markets” at the Cantor
Fitzgerald Dermatology & Aesthetics Summit at the Westin Grand Central Hotel in New York on Tuesday, June 19th at
11:00 am Eastern Time.
Dr. Rafaeli’s participation will not be webcast, but the Company’s latest investor presentation will be
available in the investor’s section of the Company’s website at www.strataskin.com.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing,
commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the
XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various
other skin conditions; and the STRATAPEN® MicroSystem, marketed specifically for the intended use of
micropigmentation.
The Company’s proprietary XTRAC® excimer laser delivers a highly targeted therapeutic beam of UVB
light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases, which impact over 35 million patients in
the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of
treatments to vitiligo patients.
STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and
utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology
clinics.
The XTRAC® business has used this proven DTC model to grow its domestic dermatology partner network
to over 740 clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC patients
an introduction to physicians prescribing a reimbursable solution, using XTRAC®, within a 10 mile radius of their
house. The Company is a leader in dermatology in-clinic business generation for its partners.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation
Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions
and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the
Company’s ability to generate the growth in its core business, the Company’s ability to develop social media marketing campaigns,
and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current
expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ
materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory and political
factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and
uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these
forward-looking statements may prove to be incorrect or unreliable. The Company assumes no duty to update its forward-looking
statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contacts:
Dr. Dolev Rafaeli, Chief Executive Officer
Jeremy Feffer, Managing Director
STRATA Skin Sciences, Inc.
LifeSci Advisors, LLC
215-619-3200
212-915-2568
ir@strataskin.com
jeremy@lifesciadvisors.com
